Massive french study tracks Real-World use of diabetes drugs in over half a million patients
NCT ID NCT05882071
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This study analyzes health records from over 547,000 people in France who started taking SGLT2 inhibitors for type 2 diabetes between 2020 and 2024. Researchers will describe patient characteristics, prescription patterns, and track the occurrence of heart attacks, strokes, heart failure, kidney problems, and safety events like ketoacidosis. The goal is to understand how these drugs are used in everyday practice and their real-world outcomes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- SGLT2 inhibitors (a class of diabetes drugs)
- What this could lead to
- If successful, this study could help doctors understand how SGLT2 inhibitors are prescribed and their real-world effects on heart, kidney, and safety outcomes in people with type 2 diabetes.
- What could go wrong
- This is an observational study using existing health data, so it cannot prove cause and effect. Results may be influenced by factors not accounted for in the data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 547,150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2023
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients in France initiating a treatment with SGLT2i between April 1, 2020, and December 31, 2024.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * population includes all patients initiating a treatment with SGLT2i between April 1, 2020, and December 31, 2024. Exclusion Criteria: * None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boehringer Ingelheim
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nurse and a neighbor help tame chronic disease?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can a vegan diet shield police officers from heart disease?
- Can a health coach in your patient portal help you lose weight?
- Common antibiotic may boost diabetes control
- Can continuous glucose monitors safely tighten hospital blood sugar control?